Supported by the phase 3 ALLEGORY trial, the application moves obinutuzumab closer to becoming a new standard for patients with active, autoantibody-positive SLE.
Women with systemic lupus erythematosus who receive immunosuppressive therapy show a higher prevalence of cervical lesions and cervical human papillomavirus infection than immunocompetent women.
Objective Cardiovascular diseases are a leading cause of morbidity and mortality in SLE. In this target population, ...
Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus ...
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License ...
Objective To investigate the relationship between adverse childhood experiences (ACEs) and health outcomes in childhood-onset ...
The systemic lupus erythematosus (SLE) market continues to evolve toward biologic-driven care, with increasing treatment complexity, intensifying competition among advanced therapies, and a robust ...
A retrospective study compared cardiovascular risks among patients with SLE who did and did not develop lupus nephritis and/or antiphospholipid antibody-positivity over time.
SSc and SLE are chronic autoimmune diseases with distinct and overlapping characteristics, including fibrosis in SSc and systemic inflammation in SLE. RNA sequencing identified differentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results